



**Universiteit
Leiden**
The Netherlands

Novel targets in the liver to treat cardiometabolic diseases Ge, X.

Citation

Ge, X. (2026, January 15). *Novel targets in the liver to treat cardiometabolic diseases*. Retrieved from <https://hdl.handle.net/1887/4286936>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4286936>

Note: To cite this publication please use the final published version (if applicable).

Novel Targets in the Liver to Treat Cardiometabolic Diseases

1. The liver determines the balance between cardiometabolic health versus disease, making it a key target for preventive and therapeutic intervention (*this thesis*).
2. Hepatic LXR activation to prevent cardiometabolic diseases should be restricted to Kupffer cells (*Kirchgessner, Cell Metab 2016; this thesis*).
3. Pharmacological inhibition of 24-dehydrocholesterol reductase (DHCR24) is a promising therapeutic strategy for metabolic dysfunction-associated steatotic liver disease (MASLD) rather than atherosclerotic cardiovascular disease (ASCVD) (*this thesis*).
4. Therapeutic strategies aimed at increasing hydrolysis of lipoprotein-phospholipids will enhance therapeutic efficacy of existing strategies to enhance hydrolysis of lipoprotein-triglycerides to reduce ASCVD risk (*Dijk, Circulation 2022; this thesis*).
5. Lipid transport within and between cells is essential for maintaining metabolic health, with ABC transporters playing a pivotal regulatory role (*Tarling, Trends Endocrinol Metab 2013*).
6. Although initially discovered in macrophages, ABCA6 is in fact involved in cholesterol transport in hepatocytes to facilitate hepatic lipoprotein clearance (*Kaminski, Biochem Biophys Res Commun 2001; this thesis*).
7. Therapeutic strategies to treat cardiometabolic diseases should take into account precise targeting of disease-relevant cell types and be multimodal to enhance therapeutic efficacy (*this thesis*).
8. “但知行好事，莫要问前程” (*冯道, 天道, 公元前 882-954*); “Simply do good, without concern for what the future holds” (*Feng Dao, Natural law, 882-954 CE*). In the context of scientific research, one should focus on conducting rigorous experiments, maintaining integrity and contributing meaningful knowledge, rather than worrying about immediate outcomes or recognition.
9. “Ever tried. Ever failed. No matter. Try again. Fail again. Fail better” (*Samuel Beckett, Worstward Ho 1983*). When applied to science: failures should be interpreted as valuable lessons rather than faults.
10. Only those without knowledge of science will interpret transgenic as transgender.